Cell :肿瘤微环境组织分布特征与肿瘤免疫反应的关系 ​

2020-08-09 雪月 BioArt

肿瘤免疫微环境是由肿瘤细胞、免疫细胞、间质细胞以及细胞外成分组成。这些组成部分的组织排列方式会影响到抗肿瘤免疫的效果。

肿瘤免疫微环境(immunetumor microenvironment iTME)是由肿瘤细胞、免疫细胞、间质细胞以及细胞外成分组成。这些组成部分的组织排列方式会影响到抗肿瘤免疫的效果。技术的发展已经能够做到可以研究肿瘤微环境中空间分布的特征。但是这些特征的临床应用价值还有待挖掘。

2020年8月6日,来自斯坦福大学Garry P. Nolan团队在Cell 上发表了题为Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front的文章。该研究探究了细胞排列结构与抗肿瘤免疫反应之间的关系。

多种成像技术可以在原位捕捉到单细胞信息。作者团队之前已经开发出称为co-detectionby indexing (CODEX)的成像系统。该成像系统结合了耦连了DNA的抗体和聚合酶、带有荧光标记的核苷酸以及可裂解的化学荧光团来实现在新鲜冷冻组织中免疫荧光成像。在其他的研究中发现细胞类型的识别可以简单的由紧邻的细胞来预测。这也表明细胞标志分子和细胞定位之间的相互关系。研究表明邻近细胞之间的关系可以预测自身免疫病模型小鼠的疾病进展。为了研究具有长期临床随访结果和生存期数据肿瘤患者的iTME,作者团队改进了CODEX系统,使该系统能够兼容于福尔马林固定、石蜡包埋的组织(formalin-fixedparaffin embedded FFPE)和组织微阵列样本(tissuemicroarrays TMAs)。

为了最大程度的识别组织中的细胞表型,作者构建了在结肠癌(colorectalcancer CRC)侵袭前沿代表性的iTME的组织微阵列样本,并用56种标记物进行成像。这些标记物可以用来识别实体瘤中与抗肿瘤免疫相关的细胞表型。通过成像确定了每个患者样本中的细胞类型(celltypes CTs),并将识别的邻近细胞(cellularneighborhoods CNs)的特征作为局部CT特征。作者同时把CT和CN信息都作为患者样本信息集合。作者将组织区域作为一个单元,即使内部单个细胞发生变化,CT和CN相对应的空间区域的变化也是相对的,组织区域依然保留其特征。

三级淋巴样结构(tertiarylymphoid structure TLS)是一种异位的类淋巴样结构,多在发生炎症的组织中形成,包括肿瘤,自身免疫,感染或同种异体移植排斥反应发生时。与肿瘤相邻的三级淋巴样结构被称为肿瘤相关的三级类淋巴样结构,包含有树突状细胞、T细胞,生发样中心以及B细胞等。在多种肿瘤中都揭示了TLS的生物学和临床意义。一种iTME特征是在肿瘤浸润前沿形成大量TLS,即形成“克罗恩样反应”(Crohn’s-likereaction CLR)。而另外一种典型的iTME特征是很少有TLS,而是出现弥漫性炎症浸润(diffuseinflammatory infiltration DII)。

先前已有研究发现,CLR患者的总体生存期比DII患者更长。两类患者之间的生存期不同可能受其抗肿瘤免疫反应差异的影响,而不仅仅是肿瘤内在的因素。作者认为使用组织成像技术比较CLR和DII患者的iTME,或许能够发现TLS以外的新型iTME结构,以探究细胞排列结构与抗肿瘤免疫反应之间的关系。

作者团队从715名CRC患者的数据集中,选择了17名CLR和18名DII患者,并选用肿瘤浸润前沿部位构建了探究iTME的TMAs。作者发现与先前报道一致,CLR患者的总体生存率明显优于DII患者。

总结成像分析发现,与CLR患者相比,DII患者肿瘤中的iTME与之有差异。在DII患者中,T细胞和巨噬细胞构成CN偶联。组织模块分析提示,在CLR患者中,肿瘤对主要免疫过程的干扰程度要比DII患者低。其次就是,CN特异性的T细胞的功能状态有所不同。在DII患者中,富集巨噬细胞的CN增加了Ki-67+ Treg细胞的富集,而富集T细胞的CN降低了Ki-67+ CD8 + T细胞的富集。富集粒细胞的CN富集的PD-1+ CD4 + T细胞的功能状态与DII患者的生存率相对较好有关。在DII患者中,巨噬细胞富集的CN抑制了T细胞富集的CN的免疫反应激活。而在CLR患者中,T细胞富集的CN和肿瘤边界上的CN之间有直接细胞间的相互作用。相反,在DII患者中,抑制性更强的巨噬细胞富集的CN则与肿瘤边界的CN有关,这表明巨噬细胞富集的CN的抑制作用可能在抗肿瘤免疫应答中起到重要作用,是影响患者生存率的重要因素。

本文提供了一种模式框架,即动态组织(如iTME)的空间生物学。分析CN及其相关性可以用来揭示其在iTME中发挥的作用,而基于CNs的功能性研究进一步阐明了其中T细胞子集之间相关性,并确定了CNs之间的通信网络。将作者开发的工具应用于大型病例队列研究,有利于发掘可能的临床标志物、治疗性的策略,也有助于理解空间组织行为如何作用于抗肿瘤免疫效应。

作者也指出他们所开发实验技术和计算框架有一定的局限性。系统适用样本要求高;所耗抗体昂贵,并且抗体种类仍然较少;成像过程所受干扰较多,有些需要手动校正,还需进一步改进系统等方面。

原始出处:

Christian M Schürch, Salil S Bhate, Graham L Barlow, et al.Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front.Cell. 2020 Jul 31;S0092-8674(20)30870-9. doi: 10.1016/j.cell.2020.07.005. Online ahead of print.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871898, encodeId=114218e189854, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 31 09:49:40 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948267, encodeId=5ea694826e0e, content=深奥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Mon Mar 15 09:10:41 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925819, encodeId=68e692581934, content=深奥, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Feb 20 14:05:38 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918992, encodeId=adb7918992fb, content=越来越复杂, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Fri Jan 22 15:19:13 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962197, encodeId=5f77196219e08, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Nov 23 02:49:40 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280225, encodeId=964e12802251d, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Tue Aug 11 01:49:40 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871898, encodeId=114218e189854, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 31 09:49:40 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948267, encodeId=5ea694826e0e, content=深奥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Mon Mar 15 09:10:41 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925819, encodeId=68e692581934, content=深奥, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Feb 20 14:05:38 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918992, encodeId=adb7918992fb, content=越来越复杂, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Fri Jan 22 15:19:13 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962197, encodeId=5f77196219e08, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Nov 23 02:49:40 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280225, encodeId=964e12802251d, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Tue Aug 11 01:49:40 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2021-03-15 ms3000001264084725

    深奥!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1871898, encodeId=114218e189854, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 31 09:49:40 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948267, encodeId=5ea694826e0e, content=深奥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Mon Mar 15 09:10:41 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925819, encodeId=68e692581934, content=深奥, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Feb 20 14:05:38 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918992, encodeId=adb7918992fb, content=越来越复杂, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Fri Jan 22 15:19:13 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962197, encodeId=5f77196219e08, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Nov 23 02:49:40 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280225, encodeId=964e12802251d, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Tue Aug 11 01:49:40 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2021-02-20 随梦飞扬

    深奥

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1871898, encodeId=114218e189854, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 31 09:49:40 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948267, encodeId=5ea694826e0e, content=深奥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Mon Mar 15 09:10:41 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925819, encodeId=68e692581934, content=深奥, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Feb 20 14:05:38 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918992, encodeId=adb7918992fb, content=越来越复杂, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Fri Jan 22 15:19:13 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962197, encodeId=5f77196219e08, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Nov 23 02:49:40 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280225, encodeId=964e12802251d, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Tue Aug 11 01:49:40 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2021-01-22 1e1ad8bdm04(暂无匿称)

    越来越复杂

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1871898, encodeId=114218e189854, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 31 09:49:40 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948267, encodeId=5ea694826e0e, content=深奥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Mon Mar 15 09:10:41 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925819, encodeId=68e692581934, content=深奥, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Feb 20 14:05:38 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918992, encodeId=adb7918992fb, content=越来越复杂, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Fri Jan 22 15:19:13 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962197, encodeId=5f77196219e08, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Nov 23 02:49:40 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280225, encodeId=964e12802251d, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Tue Aug 11 01:49:40 CST 2020, time=2020-08-11, status=1, ipAttribution=)]
    2020-11-23 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1871898, encodeId=114218e189854, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon May 31 09:49:40 CST 2021, time=2021-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948267, encodeId=5ea694826e0e, content=深奥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be85451515, createdName=ms3000001264084725, createdTime=Mon Mar 15 09:10:41 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925819, encodeId=68e692581934, content=深奥, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Feb 20 14:05:38 CST 2021, time=2021-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=918992, encodeId=adb7918992fb, content=越来越复杂, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Fri Jan 22 15:19:13 CST 2021, time=2021-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962197, encodeId=5f77196219e08, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Nov 23 02:49:40 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280225, encodeId=964e12802251d, content=<a href='/topic/show?id=2bbe289846f' target=_blank style='color:#2F92EE;'>#免疫反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28984, encryptionId=2bbe289846f, topicName=免疫反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Tue Aug 11 01:49:40 CST 2020, time=2020-08-11, status=1, ipAttribution=)]

相关资讯

Nature Cell Biology:江浩团队揭示AKAP95可通过相分离调控基因剪接和肿瘤生成

癌症常与基因表达紊乱有关, 包括在染色体、转录、mRNA剪接等水平上的调控异常。就像所有细胞内的化学反应,基因表达并非均匀分布在细胞核内,而是在时空上被分隔化了才得以正确进行和调控。

Science:CRISPR领域两大“宗师”合作,深度解析单碱基编辑器脱靶机制

首次揭开了一种“最有前途”的碱基编辑器的3D结构

盘点:用时最短!中国学者突破100篇CNS生命科学领域成果;高福/饶子和/秦川都大于4篇;上海科技大学及山东农业大学表现出色

截止2020月7月27日,中国学者在Cell,Nature 及Science 发表了共计102项生命科学的研究成果,其中新冠肺炎领域占了近一半(共43篇)。iNature系统总结了这些研究成果:

Protein Cell :姜海/张雷合作发现新型原癌基因以及Hippo通路新调控因子SHANK2

癌细胞中原癌基因的一个重要激活方式是通过所在染色体区段的局域扩增,获得基因拷贝数的增加。经典原癌基因如c-Myc、HER2、SKP2等都是主要通过这种方式激活。

“皮肤毒性反应越重,靶向治疗效果越好?”是真的吗?肿瘤专家为你详细解答

靶向药物挽救了许多肿瘤患者的生命,同时也让很多患者因为严重皮疹而痛苦不堪,为什么会出现皮疹咧?